Insilico Medicine

📢 NEWS Release | January 22, 2025 🚀 Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma Insilico Medcine announced that the first patient has been dosed in the global multicenter Phase I Trial of #ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of #mesothelioma and other solid tumors. Currently, ISM6331 is the leading #oncology program among Insilico's wholly owned AI-driven drug discovery pipelines, which was granted orphan drug designation (ODD) by the FDA for the treatment of mesothelioma. 📍 The Phase I trial conducted concurrently in China and the United States, was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of ISM6331 as a single agent in patients with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part, with the first patient enrolled in China recently, and a dose selection optimization part which will be initiated after part 1 is completed. For more information about Insilico's clinical trials please visit ClinicalTrials.gov (NCT06566079). "We are pleased to announce the dosing of the first patient in our Phase I ISM6331 clinical trial in mesothelioma and other solid tumors. We will also move forward to advance patient enrollment in the United States and accelerate the clinical translation to deliver innovative therapies that address unmet medical needs." -Sujata Rao, MD, Chief Medical Officer of Insilico Medicine See the full release in the comments 👇

🔥Insilico Medicine is proud to announce that Petrina Kamya, PhD, Global Head of AI Platforms, will lead the “Real-World Studies in AI-Driven #DrugDiscovery and Development” session at #DDIP2025 in San Diego. Welcome to the Drug Discovery Innovation Programme (DDIP) — an invitation-only event where the future of #pharmaceuticalscience takes center stage. This conference brings together the brightest minds in drug discovery to exchange insights, share experiences, and forge powerful collaborations with key industry leaders and solution providers. At DDIP, you lead the conversation! Curate your agenda to dive deep into the topics that matter most, empowering you to tackle pressing challenges and achieve actionable insights. Gain invaluable knowledge, evaluate cutting-edge technologies, and fast-track your strategic goals in a matter of days — not months. Follow along for updates, and be sure to register online here: https://bit.ly/3Q3vAMC

🛎️ Happening this week! 📍 #PMWC2025 kicks off tomorrow at the Santa Clara Convention Center. Join Insilico CBO, Michelle Chen, during the AI-Powered RWE: Accelerating Drug Development and Post-Market Applications panel. PMWC gathers recognized leaders, top global researchers and medical professionals, plus innovators across #healthcare and #biotechnology sectors. Stay tuned for more event updates, and we hope to see you there! #SiliconValley #PrecisionMedicine #ConferenceSeason

AI & Quantum Computing: Breaking Barriers in Cancer Drug Discovery 🚀 A major breakthrough from U of T & Insilico Medicine—they’ve combined AI and quantum computing to tackle the "undruggable" KRAS cancer protein. This hybrid approach designed molecules that could become future cancer treatments, potentially slashing years off traditional drug discovery timelines. 💡 Why does this matter? 🔹 KRAS mutations drive 1 in 4 human cancers, yet only two FDA-approved drugs exist. 🔹 Quantum computing + AI identified promising drug candidates faster than ever before. 🔹 This could be a game-changer for diseases once thought untreatable. 👏 Huge congratulations to Alán Aspuru-Guzik, Igor Stagljar, and the teams at University of Toronto & Insilico Medicine for advancing AI-driven drug discovery! This is a massive step toward faster, more efficient cancer therapeutics. #QuantumComputing #Biotech #AI #CancerResearch #HealthcareInnovation

Be the first to know about #Nach01 from Pharma.AI! Train accurate generative and predictive models on your data. Check out this new video below. Nach01's high precision lets you know everything you need about your molecules, whether you need ADMET properties, activity, or quantum calculations. Visit https://pharma.ai/nach01 to join the waitlist today. #PredictiveModels #Validation #3Dmolecules

✏️ Science42: #DORA aims to improve the scientific drafting process. Check out the latest video to hear about smarter navigation, improved customization, workflow improvements, and much more! Stay tuned for more exciting updates. #DORAWriting #DocumentGeneration #AbstractPapers #ReviewPapers #Conferences #AIGeneration

NEW Video 📽️ Coding the Impossible Cure--The First AI-Powered Drug with Safety and Efficacy Proved in Phase IIa As our #IPF program reaches a new clinical milestone, we're excited to update our documentary and share the joy and confidence in AI-driven drug discovery with you. In November 2024, Insilico announced positive topline data from the IPF Phase IIa study. The results demonstrate that our drug, ISM001-055, exhibits a strong safety profile and dose-dependent efficacy. This achievement marks a significant milestone in the AI-powered #drugdiscovery world, as ISM001-055 was developed using our proprietary end-to-end AI platform, Pharma.AI. Watch the latest documentary here 👉 https://lnkd.in/eZtht4yr

Meet us at BIO Europe

🚀 Happy Monday from Science42: #DORA! Here are some New Enhancements and Features now available to users: 💰 1. Pricing Table Update -We’ve added a brand-new Enterprise product option. -Now, you get a more comprehensive product description to help make informed decisions. ✏️ 2. Explore Loaded Custom Bibliography Files -Easily manage your loaded files using new “Custom Bibliography” button in the left panel. -Every loaded bibliography file now has a handy Preview/Download button for your convenience. -Find your Custom Bibliography file links right on the Bibliography right panel page when document has generated. 📃 3. Template Selection Page as Default -The template selection page is now your default view when you open DORA. Get started instantly. Clicking the Science42:DORA logo in the header now takes you straight to the template selection page.   📰 4. Document Page Settings Customization -Tailor the name of “Proposed Research Tasks” based on specific templates. ✈️ 5.   Streamlined Indication Prioritization Template -We’ve removed points related to agents and resources from the Indication Prioritization template, making your research plan more streamlined.    👉 6. Docx Export Issue -No more errors! We’ve fixed the unsupported element type: hardBreak issue during the Docx export process.    💘 7. Citation Color Formatting -Fixed color formatting for parentheses in the ‘Add Citation’ feature. Green and gorgeous! These updates are all about giving you a more efficient, user-friendly, and powerful experience with DORA. We can’t wait for you to dive in and explore these exciting new features! Visit https://pharma.ai/dora to get started today. #DORAWriting #NewFeatures #DORAUpdates #ScientificWriting

🚀 NEW LinkedIn Live, beginning tomorrow, 2/4, at 12 pm EST. Hear from Alex Zhavoronkov, PhD, on how #AI is revolutionizing #drugdiscovery. Don't miss this opportunity to gain insights from a leader in AI-driven biotechnology. Topics include: - How AI is dramatically accelerating the drug discovery process - The power of generative adversarial networks (GANs) in creating new molecules - Innovative recruitment through global hackathons - Current research in fibrosis, immunology, oncology, and CNS disorders - Strategic partnerships with major research institutions worldwide - The future of AI-powered drug development Sign up here 👉 https://lnkd.in/eVa8vT_V